에 대한 최신 뉴스 Twist Bioscience (NASDAQ:TWST) 주식

TWIST BIOSCIENCE CORP

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Ark Invest Cathie Wood

Analyst Color

Equities

Market Summary

News

Broad U.S. Equity ETFs

Futures

Markets

Analyst Ratings

ETFs

General

ILMN

TWST

아크 인베스트 설립자이자 CEO 겸 CIO인 캐시 우드는 얼굴 사진 분석을 통해 암 생존율을 발견한 매스제너럴브리검(Mass General Brigham)의 새로운 연구를 공유하며 의료 부문에서 인공지능(AI) 응용을 강조했다.

캐시 우드, 헬스케어 분야의 심도 있는 AI 응용 강조···혜택 받을 주식은?

Cathie Wood-Led Ark Invest Dumps $7M Worth Of Palantir Stock Amid Searing Rally

ACCD

ACHR

ADYEY

ARKG

ARKK

ARKQ

ARKX

EXAS

IRDM

RXRX

2025년 2월 28일 금요일 캐시 우드의 아크 인베스트가 몇 가지 주목할 만한 거래를 진행했다. 그중 가장 두드러진 것은 아처 에비에이션(NYSE:ACHR), 리커전 파마슈티컬스(NASDAQ:RXRX), 템퍼스AI(NASDAQ:TEM), 그리고 이리디움 커뮤니케이션스(NASDAQ:IRDM)의 주식을 매수한 것이다.

아크 인베스트: 템퍼스AI 및 아처 에비에이션 주식 매수, 트위스트 바이오사이언스는 매각

Cathie Wood's Flurry Of Trades: Offloads $31.5M in Tesla, Buys Amazon, AMD And Meta — Dumps Palantir, Trims Robinhood And Square Amid Bitcoin Rally

Tech

ARKF

ARKW

BEAM

IBTA

ROKU

금요일에 캐시 우드가 이끄는 아크 인베스트가 이리듐 커뮤니케이션스(NASDAQ:IRDM), 트위스트 바이오사이언스(NASDAQ:TWST), 페이저듀티(NYSE:PD), 빔 테라퓨틱스(NASDAQ:BEAM), 로쿠(NASDAQ:ROKU), 그리고 아이보타(NASDAQ:IBTA)와 같은 주식들에 대해 중요한 거래를 진행했다.

아크 인베스트의 금요일 거래, 이리듐과 트위스트 바이오사이언스를 매수, 로쿠를 매도

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

PLTR climbs higher through the day after an alert from TradePulse in the morning
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/06205125/Screenshot-2025-06-06-at-4.49.54%E2%80%AFPM-995x1024.png" alt="" class="wp-image-14058" /></figure>
Palantir Tech. Inc. (PLTR) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:48 AM on June 6th, a significant trading signal occurred for Palantir Tech. Inc. (PLTR) as it demonstrated a Power Inflow at a price of $124.90. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Palantir's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Palantir's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for PLTR, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
The price at the time of the Power Inflow was $124.90. The returns on the High price ($128.13) and Close price ($127.72) after the Power Inflow are respectively 2.6% and 2.3%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past results are not indicative of future results

Technicals

Opinion

Signals

Trading Ideas

PLTR

Palantir Rises 2.6% After Key Trading Signal

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 20 years by 22.83% on an annualized basis producing an average annual return of 31.17%. Currently, Morningstar has a market capitalization of $13.36 billion. 
Buying $100 In MORN: If an investor had bought $100 of MORN stock 20 years ago, it would be worth $23,251.58 today based on a price of $312.38 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749245429_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MORN

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Offerings

PLUG

Plug Power Files For Resale From Time To Time Of 55M Shares Of Common Stock Offered By Selling Stockholder

ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) reported quarterly losses of $(0.09) per share. This is a 12.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $250.00 thousand in sales this quarter. This is a 25.00 percent increase over sales of $200.00 thousand the same period last year.

Earnings

ZBAI

ATIF Holdings Q3 EPS $(0.09) Down From $(0.08) YoY, Sales $250.00K Up From $200.00K YoY

A feud between Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk and President Donald Trump could end Musk's ties with the White House — a development <a href="https://www.benzinga.com/interview/25/03/44539183/exclusive-tesla-protest-organizer-says-elon-musk-seems-to-have-purchased-the-american-government">welcomed by Tesla protestors</a>.
However, "the job is definitely not done,&#8221; volunteer organizer Adam Sheridan tells Benzinga.
<h3 class="wp-block-heading">Feud Comes Quicker Than Anticipated</h3>
"There was a time limit on this relationship between them," Sheridan says. 
Sheridan is a volunteer organizer with the Cooper River Indivisible <a href="https://www.cooperriverindivisible.org/" target="_blank" rel="noreferrer noopener">non-profit</a> that participates in Tesla Takedown protests.
Musk and Trump were on the same side for an election. Once that was over, there was an expiration day for their relationship, the Tesla protest organizer explained.
"I think it was predictable, but still <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45805173/musk-vs-trump-tesla-suffers-record-152b-one-day-crash-as-ceo-warns-tariffs-will-cause-a-recession">quicker [than expected],</a>&#8221; Sheridan adds.
Read Also: <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">Trump Says Musk Has &#8216;Trump Derangement Syndrome&#8217; As Battle Over Bill Heats Up: &#8216;Had A Great Relationship… Don&#8217;t Know If We Will Anymore&#8217;</a>
<h3 class="wp-block-heading">Tesla Takedown Job Not Over</h3>
Sheridan said it's too early to tell if Musk is done with the White House. The Tesla protest organizer predicts Musk will still wield political influence. 
"I think he still has a lot of power,&#8221; Sheridan says. Musk&#8217;s ownership of X, he adds, allows him to control the narrative.
"[The] White House can't ignore him."
Sheridan said Trump is an emotional guy who governs on feelings, unlike other presidents who may not have gone after Musk or his companies.
"Trump really does have an ability to hurt Elon's businesses."
For example, Trump could be "detrimental" to Musk's businesses if he makes good on <a href="https://www.benzinga.com/news/space/25/06/45808621/after-threatening-to-scrap-dragon-spacecraft-amid-tussle-with-trump-musk-backs-down-following-social-media-plea-good-advice">cutting government contracts</a>, Sheridan added.
But getting Musk out of the White House was just part of 50% of Tesla Takedown&#8217;s goal.
Sheridan said there will be protests at Tesla dealerships on June 28, which is Musk's birthday. There will also be protests in Austin, Texas around Tesla's robotaxi demonstrations, Sheridan said.
Moving on from physical protests at Tesla dealerships, Sheridan said attention may turn to economic efforts like getting pension funds to divest their Tesla stock. Sheridan also cautioned that Musk "still has a ton of power" and is threatening to launch and/or fund a third political party.
Sheridan said the goal is to continue to convince the billionaires that politics is not for them.
"Let the democratic process play out."
<h3 class="wp-block-heading">What's Next for Tesla</h3>
Sheridan warns that things could worsen for Tesla, considering Musk has fewer customers to sell to.
After catering to the left side of the political spectrum, Musk's behavior has alienated them and led to a hatred for Tesla. His campaigning catered to the MAGA (Make America Great Again) base of Trump supporters. However, if Musk is on the outs with Trump, he may be out of options. 
"Who's left? He's made enemies everywhere,&#8221; Sheridan said.
While not an analyst, Sheridan said Tesla stock price seems high given the constant flow of bad news <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45818240/tesla-stock-faces-demand-brand-issues-in-us-competition-in-china-analyst-lowers-delivery-estimates">and disappointing sales figures</a>.
Price Action: Tesla stock was up 3.7% to $295.14 on Friday. Tesla shares are down 14% over the last five days and down 22% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44963440/tesla-takedown-says-protests-are-working-hitting-ev-company-where-it-hurts-the-companys-bottom-line">Tesla Takedown Says Protests Are Working: Hitting Where It Hurts, &#8216;The Company&#8217;s Bottom Line&#8217;</a></li>
</ul>
Image: Shutterstock

Politics

Exclusives

Interview

TSLA

EXCLUSIVE: Trump Can 'Hurt Elon's Businesses,' Says Tesla Protest Organizer — But At This Point 'Who's Left' To Buy?

Management

Cyngn Donald Alvarez Steps Down As CFO And Board Member; Natalie Russell Appointed Interim CFO Effective June 6, 2025,

ROLR

High Roller Reveals Letter Of Non-Compliance With NYSE American Continued Listing Standards Received On On June 4, 2025

CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) has outperformed the market over the past 15 years by 4.43% on an annualized basis producing an average annual return of 16.43%. Currently, CACI International has a market capitalization of $9.80 billion. 
Buying $100 In CACI: If an investor had bought $100 of CACI stock 15 years ago, it would be worth $977.08 today based on a price of $445.45 for CACI at the time of writing.
<h3>CACI International's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749244513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CACI

$100 Invested In CACI International 15 Years Ago Would Be Worth This Much Today

VERO

On June 5, 2025, Venus Concept  Entered Into A Unit Purchase Agreement With Meta Robotics And MHG Co. Pursuant To Which The Company Agreed To Sell The Venus Hair Business To Meta Healthcare Group In An All-Cash Transaction Valued At $20M

SKYX

SKYX Platforms Files For Resale Of 3.5M Shares Of Common Stock By Selling Securityholders

<h3>Gainers</h3>
<ul>
<li>Lazydays Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) shares increased by 13.6% to $0.29 during Friday's after-market session. The company's market cap stands at $32.0 million. </li>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) shares rose 12.23% to $1.19. The company's market cap stands at $16.3 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares moved upwards by 11.99% to $2.8. The company's market cap stands at $7.0 million. </li>
<li>Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) stock increased by 9.99% to $1.98. The market value of their outstanding shares is at $38.9 million. </li>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) shares increased by 7.71% to $6.0. The company's market cap stands at $140.6 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares moved upwards by 7.17% to $0.89. The market value of their outstanding shares is at $17.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) stock fell 26.2% to $5.06 during Friday's after-market session. The market value of their outstanding shares is at $111.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock decreased by 11.19% to $1.35. The company's market cap stands at $22.1 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock fell 10.21% to $2.2. The company's market cap stands at $6.7 million. </li>
<li>FAT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAT#NASDAQ">FAT</a>) shares fell 9.99% to $2.24. The market value of their outstanding shares is at $39.8 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares fell 9.67% to $0.93. The market value of their outstanding shares is at $9.2 million. </li>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) stock decreased by 9.13% to $0.35. The company's market cap stands at $7.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

GDHG

GORV

NAAS

PLCE

RIME

YSXT

12 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares rose 8.2% to $14.61 during Friday's after-market session. The market value of their outstanding shares is at $211.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 6.67% to $0.43. The company's market cap stands at $1.8 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) stock rose 6.66% to $3.2. The market value of their outstanding shares is at $5.2 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock rose 6.38% to $1.64. The market value of their outstanding shares is at $27.8 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares increased by 6.25% to $0.82. The company's market cap stands at $27.1 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock rose 6.24% to $0.85. The market value of their outstanding shares is at $23.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 22.2% to $4.18 during Friday's after-market session. The company's market cap stands at $2.1 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock decreased by 9.93% to $2.45. The market value of their outstanding shares is at $6.3 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock decreased by 9.81% to $0.46. The company's market cap stands at $9.4 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock declined by 9.58% to $22.0. The market value of their outstanding shares is at $572.3 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares decreased by 8.32% to $1.43. The company's market cap stands at $10.7 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares fell 7.48% to $3.96. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

APDN

FEMY

GTBP

JUNS

LIMN

NUWE

OGEN

PTHL

TCRT

TLPH

12 Health Care Stocks Moving In Friday's After-Market Session

Bowhead Specialty Files For Mixed Shelf Of Up To $300M

<h3>Gainers</h3>
<ul>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) shares rose 34.0% to $0.35 during Friday's after-market session. The company's market cap stands at $19.3 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock rose 9.47% to $0.44. The market value of their outstanding shares is at $63.3 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock rose 8.78% to $2.6. The company's market cap stands at $50.1 million. </li>
<li>Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) stock rose 6.5% to $5.73. The company's market cap stands at $484.4 million. </li>
<li>Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) shares rose 6.47% to $10.85. The market value of their outstanding shares is at $5.9 billion. </li>
<li>Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) stock moved upwards by 5.76% to $0.43. The company's market cap stands at $13.6 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Armlogi Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOC#NASDAQ">BTOC</a>) stock decreased by 13.2% to $1.12 during Friday's after-market session. The company's market cap stands at $47.1 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares fell 8.38% to $3.49. The company's market cap stands at $9.4 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock decreased by 7.29% to $0.27. The company's market cap stands at $61.7 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock declined by 5.01% to $0.43. The market value of their outstanding shares is at $7.8 million. </li>
<li>Nixxy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) stock declined by 4.77% to $2.2. The company's market cap stands at $42.1 million. </li>
<li>ZJK Industrial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares fell 4.45% to $4.73. The company's market cap stands at $290.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTOC

CYCU

EVTL

ILAG

LNZA

Nuveen Insured California Premium Fund Ii

NIXX

SCWO

SRFM

12 Industrials Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock increased by 11.3% to $0.73 during Friday's after-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) stock rose 8.33% to $79.0. The market value of their outstanding shares is at $11.9 billion. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) stock increased by 6.15% to $1.7. The market value of their outstanding shares is at $35.7 million. </li>
<li>ClearOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>) shares moved upwards by 5.8% to $0.42. The company's market cap stands at $11.0 million. </li>
<li>Forward Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORD#NASDAQ">FORD</a>) stock rose 4.92% to $6.82. The market value of their outstanding shares is at $7.5 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock increased by 3.47% to $2.68. The market value of their outstanding shares is at $56.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) stock decreased by 6.3% to $3.29 during Friday's after-market session. The market value of their outstanding shares is at $32.1 million. </li>
<li>SiTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>) stock fell 5.0% to $195.55. The company's market cap stands at $4.6 billion. </li>
<li>Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) shares fell 4.55% to $8.2. The company's market cap stands at $95.5 million. </li>
<li>Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) stock decreased by 4.17% to $1.15. The company's market cap stands at $5.8 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares decreased by 4.11% to $3.5. The company's market cap stands at $5.3 million. </li>
<li>BIO-key International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) shares fell 4.08% to $0.82. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BKYI

BTCS

CLRO

DUOT

ENTG

FORD

MOVE

PRSO

SITM

SOBR

VRAR

12 Information Technology Stocks Moving In Friday's After-Market Session

Oceaneering International Vice President And CFO Alan R. Curtis To Retire From His Position Effective January 1, 2026.

374water Files Prospectus Relating To Sale Of Up To $100M Shares Of Common Stock From Time To Time

In the current session, the stock is trading at $417.92, after a 0.43% spike. Over the past month, Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) stock increased by 2.81%, and in the past year, by 11.80%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1749243635_0.png" alt="Past Year Chart" />

<h3>Comparing Motorola Solutions P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 84.77 in the Communications Equipment industry, Motorola Solutions Inc. has a lower P/E ratio of 34.71. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749243635_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Motorola Solutions Inc's Price Over Earnings

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) has outperformed the market over the past 15 years by 5.46% on an annualized basis producing an average annual return of 17.46%. Currently, Prestige Consumer has a market capitalization of $4.20 billion. 
Buying $1000 In PBH: If an investor had bought $1000 of PBH stock 15 years ago, it would be worth $11,018.13 today based on a price of $85.06 for PBH at the time of writing.
<h3>Prestige Consumer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749243626_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

AMZE

Amaze Holdings To Offer & Sell Up To 44.6M Shares Of Common Stock By Selling Stockholder

Press Releases

Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics

Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025

Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

Twist Bioscience Spins Out DNA Data Storage as Independent Company

Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

MannKind

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vericel

Veracyte

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Goldman Sachs

Guggenheim

Baird

JP Morgan

Barclays

아크 인베스트 설립자이자 CEO 겸 CIO인 캐시 우드는 얼굴 사진 분석을 통해 암 생존율을 발견한 매스제너럴브리검(Mass General Brigham)의 새로운 연구를 공유하며 의료 부문에서 인공지능(AI) 응용을 강조했다.
무슨 일 있었나: 캐시 우드는 앞서 언급한 의료 산업에서의 AI &#8216;심도 있는 응용&#8217;에 대해 자율주행차 및 휴머노이드 로봇에서의 구현과 비교하며 다시 한 번 강조했다.
그는 매스제너럴브리검의 연구를 강조한 Abundance360 및 엑스프라이즈의 설립자인 피터 디아만디스(Peter H. Diamandis) 박사의 말을 인용했다.
매스제너럴브리검 연구진에 따르면 AI는 얼굴 사진 분석만으로 사람의 생물학적 나이를 추정할 수 있을 뿐만 아니라 암 생존 결과 예측도 개선할 수 있었다고 한다.
이는 의료 산업에서 AI를 활용하는 데 있어 또 하나의 작은 이정표가 되었다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
While autonomous vehicles and humanoid robots are likely to be the largest applications of AI in the next five to ten years, health care is likely to be the most profound application: <a href="https://t.co/RorWkWFgSL">https://t.co/RorWkWFgSL</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1926337955272012273?ref_src=twsrc%5Etfw">May 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
그 전에도 우드는 <a href="https://www.benzinga.com/government/regulations/25/05/45344120/cathie-wood-says-ai-innovation-in-healthcare-will-be-more-profound-than-autonomous-taxi-networks-humanoid-robots" target="_blank" rel="noopener">의료 연구에 AI를 활용</a>하는 것에 대해 비슷한 언급을 한 적이 있다. 그는 "AI는 생물학적 데이터 생성부터 질병 진단, 신약 및 치료제 개발에 이르기까지 멀티오믹스의 모든 측면을 가속화하는 자기 강화 루프에 힘을 실어주고 있다"고 말했다.
멀티오믹스는 유전체학, 전사체학, 단백질체학, 대사체학 등 여러 &#8216;오믹스&#8217; 분야의 데이터를 통합하여 생물학적 시스템을 이해하는 생물학적 분석 접근법이다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
While autonomous taxi networks and humanoid robots are likely to be the largest <a href="https://twitter.com/hashtag/AI?src=hash&amp;ref_src=twsrc%5Etfw">#AI</a> applications during the next five and ten years, respectively, health care is likely to be the most profound. Thank you <a href="https://twitter.com/NMDespotARK?ref_src=twsrc%5Etfw">@NMDespotARK</a> for thought leadership in the multiomics space! <a href="https://t.co/C33JfypivU">https://t.co/C33JfypivU</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1921291392271167893?ref_src=twsrc%5Etfw">May 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
왜 중요한가: 아크 인베스트의 멀티오믹스(multiomics) 애널리스트인 네모 M. 데스팟(Nemo M Despot)은 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), 템퍼스AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 10X 지노믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) 같은 기업들이 DNA를 더 빠르고 경제적으로 시퀀싱하고 분석할 수 있는 점점 더 강력한 도구를 개발하고 있다고 강조했다.
데스팟은 AI 기반 분자 진단이 질병을 조기에 발견하고 개별 환자의 생물학적 프로필을 정밀하게 분류하는 방식을 바꾸고 있다고 말한다.
"AI는 멀티오믹스 도구와 진단의 데이터를 활용하여 더 효과적인 약물을 설계함으로써 더 빠르고 더 적은 비용으로 더 높은 성공률의 결과를 제공한다.&#8221;
사진 제공: ChrisStock82 / Shutterstock.com
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

2025년 2월 28일 금요일 캐시 우드의 아크 인베스트가 몇 가지 주목할 만한 거래를 진행했다. 그중 가장 두드러진 것은 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), 리커전 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), 템퍼스AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 그리고 이리디움 커뮤니케이션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>)의 주식을 매수한 것이다.
반면 아크 인베스트는 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), 아디옌(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADYEY#OTC">ADYEY</a>), 애콜레이드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>), 그리고 이그젝트 사이언스(NCM:EXAS)의 주식을 매도하기로 결정했다.
<h3>아처 에비에이션 거래</h3>
아크 인베스트는 아처 아비에이션의 주식을 세 개의 ETF를 통해 상당량 매수했다. ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)가 360,583주, ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)가 54,699주, ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)가 17,322주를 매수했다.
금요일 종가 8.88달러 기준 아처 에비에이션 매수 거래 총 가치는 약 380만 달러이다.
<h3>리커전 파마슈티컬스 및 템퍼스AI 거래 </h3>
아크 인베스트는 리커전 파마슈티컬스와 템퍼스AI에도 강한 관심을 보였다. <a href="https://www.benzinga.com/markets/equities/25/02/43963343/cathie-woods-buys-the-dip-in-tempus-ai-coinbase-but-sells-arks-bitcoin-etf-shares-amid-crypto-meltdown">이전에</a> 아크 인베스트는 템퍼스AI의 주식을 상당량 매수했지만, 4분기 엇갈린 실적 발표 이후 템퍼스AI 주가는 하락했다.
아크 인베스트의 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)가 리커전 파마슈티컬스 주식 268,467주와 템퍼스AI의 주식 32,467주를 매수했다.
또한 ARK Innovation ETF가 리커전 파마슈티컬스 주식 384,956주와 템퍼스AI의 주식 49,250주를 매수했다.
템퍼스AI의 경우 종가 56.18달러, 리커전 파마슈티컬스 경우 종가 7.51달러 기준, 이 거래의 총 가치는 각각 3,670만 달러, 61만 달러이다.
<h3>기타 거래</h3>
아크 인베스트의 의 ARK Innovation ETF가 이리디움 커뮤니케이션스의 주식 73,659주를 매수한 반면, 트위스트 바이오사이언스의 주식 65,290주를 매도했다.
또한 ARK Next Generation Internet ETF가 아디옌의 주식 52주를 소량 매도했다.
그리고 ARK Genomic Revolution ETF는 이그젝트 사이언스의 주식 80,270주와 애콜레이드의 주식 232주를 매도했다.
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
사진 출처: 아크 인베스트
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

금요일에 캐시 우드가 이끄는 아크 인베스트가 이리듐 커뮤니케이션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), 그리고 아이보타(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NASDAQ">IBTA</a>)와 같은 주식들에 대해 중요한 거래를 진행했다.
IRDM 거래
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 이리듐 커뮤니케이션스의 주식 86,666주를 매수했다.
금요일에 IRDM의 종가가 31.63달러이었으므로, 이 거래의 총 가치는 약 274만 달러입니다. 이 움직임은 IRDM 주가가 약간 하락한 가운데 이루어졌으며, 금요일에 주가가 1.13% 변화했다.
TWST 거래
아크 인베스트는 또한 ARKK를 통해 트위스트 바이오사이언스의 주식 36,806주를 구매했다.
종가가 47.59달러였으므로, 이 거래의 총 가치는 약 175만 달러이다. TWST의 주가가 금요일에 1.5% 이상 급등했다.
PD 거래
아크 인베스트는 ARKK를 통해 페이저듀티의 주식 35,546주를 매수하고, 추가로 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 10,215주를 매수했다.
금요일에 PD의 종가가 19.3달러이었으므로, 이 거래의 총 가치는 약 882,000달러이다.
기타 주요 거래:
<ul>
<li>아크 인베스트는 아이보타(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NASDAQ">IBTA</a>)의 주식 24,250주를 ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)를 통해 매수했다.</li>
<li>아크 인베스트는 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>)의 주식 1,916주를 ARK Genomic Revolution ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#NYSE">ARKG</a>)와 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 매수했다.</li>
<li>아크 인베스트는 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)의 주식 46,810주를 ARKK와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 매도했다.</li>
</ul>
이 거래들은 기술 섹터의 역동적인 성과에 대한 아크 인베스트의 전략적 결정을 반영한다.
 
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/02/43755136/bill-gates-wanted-a-friend-to-take-charge-of-microsoft-due-to-regret-over-leaving-harvard-but-heres-why-he-panick">빌 게이츠는 하버드를 떠난 것을 후회하여 친구가 마이크로소프트의 &#8216;책임을 맡기를 원했지만, 그가 패닉에 빠져 중퇴한 이유는?</a></li>
</ul>
면책 조항: 이 콘텐츠는 AI 도구의 도움을 받아 부분적으로 생성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
이미지 제공: Ark Invest


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

캐시 우드가 이끄는 아크 인베스트가 월요일(10일)에 상당한 규모의 거래를 했다. 가장 눈에 띄는 것은 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) 주식의 매각이었는데, 팔란티어 주가가 인상적인 재무 실적 이후 계속 상승세를 이어가고 있었기 때문이다.
<h3>팔란티어 거래</h3>
월요일, 아크 인베스트가 팔란티어의 ARKK ETF를 통해 135,775주를 매각하는 주목할 만한 거래를 실행했다. 이 움직임은 팔란티어의 주가가 인상적인 <a href="https://in.benzinga.com/news/earnings/earnings-beats/25/02/43468342/palantir-rockets-on-strong-q4-2024-was-only-a-dress-rehearsal-for-ai-growth-says-analyst" target="_blank" rel="noopener">4분기 실적 보고서를 발표</a>하고 주가가 <a href="https://www.benzinga.com/25/02/43550434/cathie-wood-dumps-10-million-palantir-shares-at-peak-sells-robinhood-and-reddit-ark-invest-loads-up-on-qualcomm-stock" target="_blank" rel="noopener">사상 최고치를 경신한 이후에 나온 것이다</a>. 팔란티어는 매출 8억 2,752만 달러를 기록해 애널리스트들의 예상치인 7억 7,591만 달러를 넘어섰고, 주당 14센트의 조정 수익을 기록해 주당 11센트의 예상치를 상회했다.
팔란티어의 월요일 종가는 116.65달러로 5.23% 상승했다. 52주 최고가는 116.76달러였고, 월요일 시간외 거래에서는 117.56달러에 거래되었다. 월요일 종가를 기준으로 아크 인베스트의 팔란티어 매각액은 약 1,583만 달러에 달한다. 아크 인베스트는 인상적인 재무 실적에도 불구하고 팔란티어에 대한 지분을 <a href="https://www.benzinga.com/25/02/43550434/cathie-wood-dumps-10-million-palantir-shares-at-peak-sells-robinhood-and-reddit-ark-invest-loads-up-on-qualcomm-stock" target="_blank" rel="noopener">전략적으로 줄이고 있다.</a>
<h3>기타 주요 거래</h3>
<ul>
<li>유아이패스 (PATH) – ARKK 통해 459,205주, ARKW 통해 33,061주 매각</li>
<li>로쿠 (ROKU) – ARKK 통해 78,654주 매각</li>
<li>트위스트 바이오사이언스 (TWST) – ARKK 통해 268,210주 매입</li>
<li>일루미나 (ILMN) – ARKK 통해 85,621주, ARKG 통해 14,846주 매입</li>
</ul>
이미지 출처: Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

PATH

아크 인베스트, 팔란티어 주식 1,600만 달러 상당 추가 매각

금요일에 캐시 우드의 아크 인베스트가 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) 그리고 로블록스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) 등 여러 주요 기업의 주식에 대해 중요한 거래를 진행했다.
AMZN 거래
아크 인베스트는 ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) 그리고 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) 펀드를 통해 아마존닷컴 주식을 구매했다. 모든 ETF를 합쳐 총 72,457주의 주식을 매수했다.
아마의 당일 종가가 229.15달러였음을 감안할 때, 총 매입금액은 1,660만 달러이다.
로블록스 거래
아크 인베스트는 ARKF, ARKK 그리고 ARKW 펀드를 통해 로블록스 주식 48,541주를 매수했다. 로블록스 주식의 금요일 종가가 66.28달러일 때, 이 거래의 가치는 321만 달러이다.
일루미나 거래
아크 인베스트는 ARKG와 ARKK 펀드를 통해 일루미나 주식 107,459주를 매수했다. 금요일 일루미나 주식의 종가가 111.06달러일 때, 이 거래의 가치는 1,193만 달러이다.
PLTR 거래
아크 인베스트는 ARKF 펀드에서 팔란티어 주식 8,150주를 매도했다. 금요일 팔란티어 주식의 종가가 110.85달러일 때, 이 거래의 가치는 903,428달러이다. 알렉스 카프가 이끄는 이 회사는 목요일에 주가가 116달러로 사상 최고가를 기록했다.
기타 주요 거래
<ul>
<li>애콜레이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>): ARKG 펀드를 통해 401,962주 매도.</li>
<li>트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): ARKG와 ARKK 펀드를 통해 44,562주 매수.</li>
<li>10X 지노믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): ARKG와 ARKK 펀드를 통해 185,249주 매수.</li>
<li>페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>): ARKK와 ARKW 펀드를 통해 85,420주 매수.</li>
<li>클라우드플레어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>): ARKW 펀드를 통해 18,319주 매도.</li>
<li>유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): ARKK와 ARKW 펀드를 통해 996,441주 매도.</li>
<li>로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): ARKF, ARKK, ARKW 펀드를 통해 113,777주 매도.</li>
<li>로켓랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>): ARKQ와 ARKX 펀드를 통해 70,252주 매도.</li>
</ul>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A0%84%EC%84%A4%EC%A0%81%EC%9D%B8-%EA%B3%B5%EB%A7%A4%EB%8F%84-%ED%88%AC%EC%9E%90%EC%9E%90-%EC%A7%90-%EC%B0%A8%EB%85%B8%EC%8A%A4-%EC%97%AD%EC%82%AC%EC%A0%81%EC%9D%B8-%EA%B7%B9%EB%8B%A8%EC%97%90/" target="_blank" rel="noopener">전설적인 공매도 투자자 짐 차노스가 시장 투기가 역사적 극단치에 이르렀다고 경고했습니다: ‘월스트리트도 화폐 인쇄기가 있습니다&#8217;</a></li>
</ul>
사진 출처: Ark Invest
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Short Sellers

AMZN

HOOD

RBLX

RKLB

아크 인베스트는 팔란티어 지분을 줄이고 아마존, 로블록스 및 일루미나에 대한 큰 베팅

아크 인베스트먼트 매니지먼트 설립자이자 CEO인 캐시 우드는 최근 소파이(SoFi)의 투자 전략 책임자 리즈 토마스(Liz Thomas)와 함께 출연한 팟캐스트에서 기술 혁신의 초석으로 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)를 강조하고, 인공지능(AI) 투자의 미래를 옹호했다.
무슨 일 있었나: ARK 이노베이션 ETF를 이끄는 것으로 널리 알려진 캐시 우드는 테슬라를 "지구상에서 가장 큰 AI 프로젝트"라고 표현하며 여러 분야에 걸쳐 AI의 혁신적 잠재력을 강조했다.
특히 AI와 시퀀싱 기술의 융합이 혈액 검사를 통한 암 진단, 특히 크리스퍼 유전자 편집 기능과 결합될 경우 암 진단에 혁신을 가져올 수 있는 의료 분야의 발전에 주목했다.
우드는 주요 기술 기업들의 막대한 GPU 및 클라우드 인프라 투자에 대한 우려를 언급하며 자본 지출 증가에 대한 투자자들의 회의적인 시각도 인정했다.
그는 아직 명확한 수익이 입증되지 않은 투자의 예로 18개월 만에 300억 달러에서 600억 달러로 지출이 급증한 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)를 들었다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C-%EB%B0%94%EC%9D%B4%EC%98%A4-%EB%B6%84%EC%95%BC%EC%97%90%EC%84%9C-4%EC%B2%9C%EC%96%B5-%EB%8B%AC%EB%9F%AC-%EA%B8%B0%ED%9A%8C-%EC%A0%84%EB%A7%9D/">캐시 우드, 바이오 분야에서 4천억 달러 기회 전망</a>
왜 중요한가: 캐시 우드의 이번 발언은 주력 펀드를 통해 테슬라 보유 자산을 1,800만 달러 줄이는 등 최근 포트폴리오 조정 과정 속에 나왔다. 이러한 매각에도 불구하고 우드는 "1조 달러 이상의 수익 기회"를 예상하며 테슬라의 <a href="https://www.benzinga.com/24/11/42205945/ark-invests-bold-move-tesla-shares-sold-amid-market-shifts" target="_blank" rel="noopener">자율주행 잠재력</a>에 대해 낙관적인 장기 전망을 유지하고 있다.
우드의 투자 논리는 테슬라를 넘어 광범위한 생물학 분야로 확장되어 AI, 유전자 염기서열 분석, <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared" target="_blank" rel="noopener">유전자 편집 기술</a>의 융합으로 4,000억 달러의 시장 기회가 창출될 것으로 예상하고 있다.
11억 7,900만 달러의 자산을 운용하는 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 이러한 신념을 반영하여 트위스트 바이오사이언스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), CRISPR 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) 같은 회사에 상당한 투자를 단행했다.
우드는 시장 밸류에이션 상승에 대한 우려에 대해 현재 20대 초반의 시장 멀티플은 오류의 여지가 거의 없다고 지적했다. 그러나 특히 AI와 의료 혁신의 교차점에서 <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared" target="_blank" rel="noopener">질병 치료 및 진단</a>의 혁신적인 발전 가능성을 보는 비즈니스 모델의 출현에 대해 여전히 확신을 가지고 있다.
이미지 출처: 아크 인베스트
면책 조항: 이 기사는 부분적으로 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>의 도움으로 작성되었으며 Benzinga 편집자가 검토 후 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Global

CRSP

캐시 우드 "테슬라는 지구상에서 가장 큰 AI 프로젝트", 기술 투자에 대해 우려하지 않아

Comments

Twist Bioscience

뉴스

에 대한 최신 뉴스 Twist Bioscience (NASDAQ:TWST) 주식

월요일, 5월 26, 2025

토요일, 3월 01, 2025

토요일, 2월 15, 2025

화요일, 2월 11, 2025

일요일, 2월 09, 2025

금요일, 11월 29, 2024

수요일, 11월 27, 2024

금요일, 11월 01, 2024

월요일, 9월 16, 2024

목요일, 5월 09, 2024

수요일, 5월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌